Navigation Links
$13 million federal grant for research into vascular disease awarded to Weill Cornell

NEW YORK (Jan. 16, 2008) -- The National Heart, Lung, and Blood Institute (NHLBI) has awarded another $13 million grant to the Center of Vascular Biology at Weill Cornell Medical College in New York City for biomedical research into vascular disease -- specifically atherosclerosis and thrombosis, which are major risk factors for coronary artery disease, heart attack and stroke.

The Program Project Grant awarded to Drs. Katherine and David Hajjar represents a renewal of five ongoing projects that have already made major contributions -- elucidating the biology of cells of the artery wall, the blood cells with which they interact, and the principal cellular and genetic changes that take place in arteries that predispose them to the formation of plaque and blood clots.

The projects will continue investigations of the interactions between blood cells and vessels, testing the hypothesis that mediators -- substances including nitrogen oxides, reactive oxygen species and growth factors -- regulate blood-vessel cell activity and plaque formation, and that atherosclerosis acts like a blood clot, forming a "response to injury."

"Perhaps the greatest strength of Weill Cornell's Vascular Biology Program, which began 17 years ago, is its record of high-quality, collaborative scientific interactions and outstanding scientists who trained in this Center over the years. The complementary scientific strengths and discrete research talents of our investigators create effective research synergies and enhance the scope of our research goals," says Dr. David P. Hajjar, executive vice provost and senior executive vice dean of Weill Cornell Medical College, and dean and Frank H.T. Rhodes Distinguished Professor of Cardiovascular Biology and Genetics at Weill Cornell Graduate School of Medical Sciences.

In 1995, Weill Cornell Medical College established a Center of Vascular Biology headed by Dr. David Hajjar. Institutional funds in excess of $5 million were designated for capital improvements, equipment and faculty development to support the program.

The five NHLBI Program Project Grant projects include the following:

  • Dr. Aaron J. Marcus (Medicine) leads a study of CD39 NTPDase1. The goal is to understand the critical role of the compound as the prime regulator of blood fluidity and thrombosis.

  • Dr. Katherine A. Hajjar (Cell Biology) leads a study of the stress response in vascular cells of Annexin 2, a receptor that mediates the breakdown of a blood clot, as it relates to atherosclerosis.

  • Dr. Barbara L. Hempstead (Medicine) leads a study on the role of Brain-Derived Neurotrophic Factor (BDNF) in the promotion of blood-vessel formation in heart-attack patients.

  • Dr. Steven S. Gross (Pharmacology) leads a study of mitochondria (a kind of cellular power plant) in the function and dysfunction of eNOS (endothelial nitric oxide synthase), an enzyme that relaxes the smooth muscle in blood vessels.

  • Dr. David P. Hajjar (Biochemistry & Pathology) leads a study on the activation of the enzyme cyclooxygenase (COX) in atherosclerosis by nitrogen oxide and the impact of this activation on atherogenesis (plaque formation).

By the end of this 20-year program in 2011, it is hoped that the array of molecular links that define atherogenesis and thrombosis will have been identified.


Contact: Andrew Klein
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College

Related biology news :

1. Structure of 450 million year old protein reveals evolutions steps
2. First orchid fossil puts showy blooms at some 80 million years old
3. SyntheMed Completes $2.8 Million Equity Financing
4. Rutgers Genetics receives $7.8 million for autism research
5. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
6. UD leads $5.3-million research project on rice epigenetics
7. Rutgers high school outreach gets $3 million boost from NSF
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. UD leads $5.3-million research project on rice epigenetics
10. $22 million gift from Alfred Taubman launches new biomedical research institute
11. Nanobiosym awarded $2 million DTRA contract
Post Your Comments:
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... Lemonade Stand Foundation (ALSF), a leading national childhood cancer ... bioinformatics lab, using ,big data, to advance the pace ... Liz Scott , co-executive director of ALSF and Alex,s ... Washington, D.C. , hosted by Vice President ... pediatric cancer research and awareness. The ...
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
Breaking Biology Technology: